Abstract
Tumor-associated antigens can be demonstrated on different tumors in mice and humans1. However, immune responses to tumor antigens have typically shown low efficacy and do not prevent tumor growth in immunocompetent hosts. Many factors contribute to the escape of tumors from immunological control, including defects in antigen-presentation and expression of immunosuppressive molecules. In addition, tumors might have developed alternative intrinsic mechanisms against increased exposure to leukocytes.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
E. M. Jaffee and D. M. Pardoll. Murine tumor antigens: is it worth the search?. Cur. Opin. Immunol. 8: 622–627 (1996).
D. Hanahan. Heritable formation of pancreatic beta cell tumours in transgenic mice expressing recombinant insulin/simian virus 40 oncogenes. Nature. 315: 115–122 (1985).
T. E. Adams, S. Alpert and D. Hanahan. Non-tolerance and autoantibodies to a transgenic selfantigen expressed in pancreatic β cells. Nature. 325: 223–228 (1987).
C. Jolicoeur, D. Hanahan and K. M. Smith. T-cell tolerance toward a transgenic β-cell antigen and transcription of endogenous pancreatic genes in thymus. Proc. Natl. Acad. Sci. USA. 91: 6707–6711 (1994).
B. E. Elliot, D. A. Carlow, A.-M. Redricks and A. Wade. Perspectives on the role of MHC antigens in normal and malignant cell development. Adv. Cancer Res. 53: 181–244 (1989).
C. Lieping, P. S. Linsley and K. E. Hellström. Costimulation of T cells for tumor immunity. Immunol. Today. 14: 483–486 (1993).
B. Mukherji and N. G. Chakraborty. Immunobiology and immunotherapy of melanoma. Curr. Opin. Oncol. 7: 175 (1995).
M. Hahne, D. Rimoldi, M. Schröter, P. Romero, M. Schreier, L. E. French, P. Schneider, T. Bornand, A. Fontana, D. Lienard, J.-C. Cerottini, J. Tschopp. Melanoma cell expression of Fas (Apo-1/Cd95) ligand: implications for tumor immune escape. Science. 274: 1363–1366 (1996).
F. Radvanyl, S. Christgau, S. Baekkeskov, C. Jolicoeur and D. Hanahan. Pancreatic β cells cultured from individual preneoplastic foci in a multistage tumorigenesis pathway: a potentially general technique for isolating physiologically representative cell lines. Mol. Cell. Biol. 13: 4223–4232 (1993).
K. Hamaguchi and E. H. Leiter. Comparison of cytokine effects on mouse pancreatic α cell and β cell lines. Viability, secretory function, and MHC antigen expression. Diabetes. 39: 415–425 (1990).
T. A. Springer. Adhesion receptors of the immune system. Nature. 346: 425–434 (1990).
S. V. Onrust, P. Hartl, S. D. Rosen and D. Hanahan. Modulation of L-selectin ligand expression during an immune response accompanying tumorigenesis in transgenic mice. J. Clin. Invest. 97: 54–64 (1996).
P. R. Streeter, B. T. N. Rouse and E. C. Butcher. Immunohistologic and functional characterization of a vascular addressin involved in lymphocyte homing into peripheral lymphnodes. J. Cell. Biol. 107: 1853–1862 (1988).
J.-R Girard and T. A. Springer. High endothelial venules (HEVs): specialized endothelium for lymphocyte migration. Immunol. Today. 16: 449–457 (1995).
I. Förster, R. Hirose, J. M. Arbeit, B. E. Clausen and D. Hanahan. Limited capacity for tolerization of CD4+ T cells specific for a pancreatic β cell neo-antigen. Immunity. 2: 573–585 (1995).
D. L. Müller, M. K. Jenkins, R. H. Schwartz. Clonal expansion vs. functional clonal inactivation: a costimulatory pathway determines the outcome of T cell receptor occupancy. Annu. Rev. Immunol. 7: 445–480 (1989).
J. P. Allison, A. A. Hurwitz and D. R. Leach. Manipulation of costimulatory signals to enhance antitumor T-cell response. Curr. Opin. Immunol. 7: 682–686 (1995).
T.C. Wu, A. Y. C. Huang, E. M. Jaffee, H. I. Levitzky and D. M. Pardoll. A reassessment of the role of B7-1 expression in tumor rejection. J. Exp. Med. 182: 1415–1421 (1995).
L. Chen, P. McGowan, S. Ashe, J. Johnston, Y. Li, I. Hellström and K. E. Hellström. Tumor immunogenicity determins the effect of B7 costimulation on T cell-mediated tumor immunity. J. Exp. Med. 179: 523–532 (1994).
S. Guerder, D. E. Picarella, P. S. Linsley and R. A. Flavell. Costimulator B7-1 confers antigen-presenting-cell function to parenchymal tissue and in conjunction with tumor necrosis factor a leads to autoimmunity in transgenic mice. Proc. Natl. Acad. Sci. USA. 91: 5138–5142 (1994).
J. Folkman, K. Watson, D. Ingber and D. Hanahan. Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature. 339: 58–61 (1989).
A. W. Griffioen, CA. Damen, G. H. Blijham and Groenewegen. Tumor angigogenesis is accompanied by a decreased inflammatory response of tumor-associated endothelium. Blood. 88: 667–0673 (1996).
N. Z. Wu, B. Lkitzman, R. Dodge and M. Dewhirst. Diminished leukocyte-endothelium interaction in tumor microvessels. Cancer Res. 52: 4265–4268 (1992).
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1998 Springer Science+Business Media New York
About this chapter
Cite this chapter
Ganss, R., Hanahan, D. (1998). Failure of Tumor Immunity Resulting from Inaccessibility of Activated Lymphocytes to Solid Tumors. In: Mihich, E., Croce, C. (eds) The Biology of Tumors. Pezcoller Foundation Symposia, vol 9. Springer, Boston, MA. https://doi.org/10.1007/978-1-4899-1352-4_8
Download citation
DOI: https://doi.org/10.1007/978-1-4899-1352-4_8
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4899-1354-8
Online ISBN: 978-1-4899-1352-4
eBook Packages: Springer Book Archive